$15.33
Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
Aurinia Pharmaceuticals Initiates Phase 4 PRESERVE Study in Lupus Nephritis Combination Therapy
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
Overview
52-week range
$7.29
$17
84% of range
Avg surprise (last 3)
+44.3%
Avg reaction (last 2)
-2.7%
50% positive
Latest IV / EM
60%
EM ±13.7% · $15 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $0.25 | $0.18 | +38.9% | +56.2% | -6.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.23 | — | — | — | — | financials |
| Thu Jul 31, 2025 | Jun/2025 | $0.16 | $0.17 | -5.9% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $0.16 | $0.08 | +100.0% | — | +1.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.10 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.01 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.07 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.09 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.08 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | OTHER | $0.19 | $0.16 | +18.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $78M | — | $73M | $70M | $62M | — | $68M | $57M |
| Cost of revenue | $7M | — | $8M | $7M | $9M | — | $6M | $9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $41M | — | $30M | $20M | $22M | — | $12M | $-2M |
| Net income | $34M | — | $32M | $22M | $23M | — | $14M | $722,000 |
| EPS (diluted) | $0.25 | — | $0.23 | $0.16 | $0.16 | — | $0.10 | $0.01 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $41M | — | $73M | $53M | $66M | — | $37M | $33M |
| Inventory | $46M | $46M | $45M | $47M | $46M | $39M | $39M | $39M |
| Total current assets | $480M | $492M | $439M | $409M | $406M | $447M | $440M | $410M |
| Total assets | $724M | $752M | $528M | $503M | $505M | $551M | $549M | $524M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $156M | $170M | $162M | $167M | $155M | $173M | $161M | $159M |
| Total equity | $568M | $581M | $366M | $335M | $350M | $377M | $388M | $365M |